Canterbury DHB


MGUS Prognosis

Clinically, the main reason to separate MGUS from Smouldering Myeloma (SMM) is that the risk of progression to symptomatic myeloma is different (1% per year for MGUS versus 10% per year for SMM).

Other factors may assist in predicting when the transformation to myeloma will occur. An abnormal Serum Free Light Chain ratio and a non-IgG M protein carry a higher risk of transformation (see Rajkumar et al Lab Findings and Prognosis, MGUS and SMM).

About this Canterbury DHB document (39809):

Document Owner:

Amy Holmes (see Who's Who)

Last Reviewed:

September 2014

Next Review:

September 2016


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 39809